Atria Wealth Solutions Inc. Sells 11,195 Shares of GSK PLC Sponsored ADR $GSK

Key Points

• Atria Wealth Solutions Inc. significantly reduced its holdings in GSK PLC by 53.9%, leaving them with 9,570 shares worth $371,000.
• GSK shares received mixed ratings from analysts, with a recent upgrade from a "hold" to a "buy" rating by Wall Street Zen.
• The company recently announced a quarterly dividend of $0.4206, translating to an annualized yield of 4.3%, with a payout ratio of 79.17%.

Atria Wealth Solutions Inc. reduced its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 53.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,570 shares of the pharmaceutical company's stock after selling 11,195 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in GSK were worth $371,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Costello Asset Management INC purchased a new position in shares of GSK in the first quarter worth $31,000. Probity Advisors Inc. grew its holdings in GSK by 27.0% in the 1st quarter. Probity Advisors Inc. now owns 19,201 shares of the pharmaceutical company's stock worth $744,000 after acquiring an additional 4,081 shares during the last quarter. IFG Advisory LLC increased its position in shares of GSK by 10.1% in the first quarter. IFG Advisory LLC now owns 17,717 shares of the pharmaceutical company's stock valued at $686,000 after acquiring an additional 1,624 shares during the period. ProVise Management Group LLC raised its stake in shares of GSK by 2.4% during the first quarter. ProVise Management Group LLC now owns 114,751 shares of the pharmaceutical company's stock valued at $4,445,000 after acquiring an additional 2,700 shares during the last quarter. Finally, US Bancorp DE grew its stake in shares of GSK by 5.9% in the first quarter. US Bancorp DE now owns 170,871 shares of the pharmaceutical company's stock worth $6,620,000 after purchasing an additional 9,473 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Up 0.5%

Shares of NYSE GSK traded up $0.19 during mid-day trading on Tuesday, hitting $39.26. 666,413 shares of the stock traded hands, compared to its average volume of 5,176,506. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The company has a market cap of $80.05 billion, a price-to-earnings ratio of 18.16, a PEG ratio of 1.71 and a beta of 0.51. The stock has a fifty day moving average price of $38.47 and a 200-day moving average price of $38.02. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The company had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. GSK's revenue was up 1.3% on a year-over-year basis. During the same period last year, the company posted $0.43 EPS. Research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.3%. GSK's dividend payout ratio is presently 77.78%.

Analyst Ratings Changes

A number of research analysts have commented on GSK shares. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.